Circulating and Adipose Tissue mRNA Levels of Zinc-α2-Glycoprotein, Leptin, High-Molecular-Weight Adiponectin, and Tumor Necrosis Factor-Alpha in Colorectal Cancer Patients With or Without Obesity

Huijuan Zhu1†, Meijuan Liu1†, Nianrong Zhang1, Hui Pan1, Guole Lin2, Naishi Li1, Linjie Wang1, Hongbo Yang1, Kemin Yan1 and Fengying Gong1*

1 Key Laboratory of Endocrinology of National Health and Family Planning Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China
2 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China

Objectives: To explore zinc-α2-glycoprotein (ZAG), leptin, high-molecular-weight adiponectin (HMW-ADPN), and tumor necrosis factor-alpha (TNF-α) levels in serum and subcutaneous and visceral white adipose tissue (sWAT and vWAT) among normal weight (NW) and overweight/obese (OW/OB) patients with colorectal cancer (CRC).

Methods: A total of 76 Chinese CRC patients (42 NW + CRC, 34 OW/OB + CRC) and 40 healthy controls were recruited. Serum levels of the adipokines of interest were measured by an enzyme-linked immunosorbent assay method, and their mRNA levels in sWAT and vWAT were determined by reverse transcription quantitative PCR methods.

Results: Serum ZAG levels in the NW + CRC group were significantly increased by 11.7% compared with the healthy controls. Serum leptin levels in the OW/OB + CRC group were found to be increased by 57.7%, while HMW-ADPN levels were decreased by 23.5% when compared with the NW + CRC group of CRC patients. Additionally, ZAG mRNA levels in sWAT were significantly reduced by 78.8% in OB + CRC in comparison with NW + CRC patients. ZAG mRNA levels were negatively associated with body mass index (BMI) in sWAT but positively correlated with BMI in vWAT. TNF-α mRNA levels in vWAT of OB + CRC patients were significantly increased by 2.8-fold when compared with NW + CRC patients. In particular, CRC was independently associated with serum ZAG levels. The risk of CRC in participants with high tertile serum ZAG levels was 5.84-fold higher than in those with low tertile ZAG levels after adjusting for age, gender, and other confounders [odds ratio (OR) = 6.84, 95% confidence interval (CI) 1.70–27.54, P = 0.03].

The area under the receiver operating characteristic (ROC) curve of ZAG was 0.66 (95% CI 0.54–0.77, P < 0.05). At the cutoff value of 1.42 µg/mL serum ZAG, the sensitivity and specificity for differentiating patients with CRC from controls were 62.2 and 69.2%, respectively.

Citation: Zhu H, Liu M, Zhang N, Pan H, Lin G, Li N, Wang L, Yang H, Yan K and Gong F (2018) Circulating and Adipose Tissue mRNA Levels of Zinc-α2-Glycoprotein, Leptin, High-Molecular-Weight Adiponectin, and Tumor Necrosis Factor-Alpha in Colorectal Cancer Patients With or Without Obesity. Front. Endocrinol. 9:190. doi: 10.3389/fendo.2018.00190
INTRODUCTION

Colorectal cancer (CRC) is the third most predominant cancer in men and the second in women around the world (1). Approximately one million new cases of CRC are diagnosed every year, and half a million people die yearly from this cancer worldwide (2). Though the etiology and pathogenesis of CRC is still unclear, a growing body of evidence has shown that obesity, particularly visceral obesity, is a risk factor for CRC (3, 4). It has been reported that the risk of CRC increases by 7 and 4%, respectively, for every 2 kg/m² increase in body mass index (BMI) or 2 cm increase in waist circumference (4). Furthermore, increasing adiposity may influence its prognosis, including the recurrence, disease-free survival, and mortality of patients with CRC (5).

Although the mechanisms by which obesity contributes to the occurrence and development of CRC are multifactorial and have not yet been fully elucidated, accumulating evidence has shown that adipose tissue dysfunction in obesity, which causes an alteration of adipokine secretion, may mediate the relationship between obesity and CRC (6–8). Among these adipokines, adiponectin, leptin, and tumor necrosis factor-alpha (TNF-α) have been largely reported to be implicated in the development of CRC. Recent studies reported a significant inverse association of total and high-molecular-weight adiponectin (HMW-ADPN) with colorectal adenoma (9), not only for early CRC but also for advanced CRC patients (10). Studies in Western populations performed by Kumar and Salageanu et al. observed significantly lower serum leptin levels in CRC patients than in controls (11, 12). Additionally, a case-control study performed by Joshi et al. in a South Korean population found a negative association between leptin and CRC risk (13). TNF-α is usually considered to be a powerful anticancer agent because of its ability to induce necrosis of cancers. However, in recent years, accumulating evidence has demonstrated that TNF-α is increased during obesity (14) and may serve as a pro-cancer cytokine that is involved in carcinogenesis and cancer progression (15, 16). Higher serum levels of TNF-α have been shown to be associated with an increased risk of colorectal adenomas (17).

Conclusion: Serum ZAG levels were significantly increased in CRC patients. Subjects with higher circulating ZAG and lower leptin levels were more likely to have CRC than those with lower ZAG and higher leptin levels. Serum ZAG might be a potential diagnostic biomarker for CRC in the Chinese population.

Keywords: colorectal cancer, adipokines, zinc-α2-glycoprotein, obesity, leptin

Abbreviations: CRC, colorectal cancer; sWAT, subcutaneous white adipose tissue; vWAT, visceral white adipose tissue; NW, normal weight; OW/OB, overweight/obese; ZAG, zinc-α2-glycoprotein; HMW-ADPN, high-molecular-weight adiponectin; TNF-α, tumor necrosis factor-alpha; ELISA, enzyme-linked immunosorbent assay; ROC, receiver operating characteristic; BMI, body mass index; AUC, area under the curve; CA19-9, carbohydrate 19-9; CEA, carcinoembryonic antigen; sBP, systolic blood pressure; dBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FPG, fasting blood glucose; RT-qPCR, reverse transcription quantitative PCR; SD, standard deviation; OR, odds ratio; CI, confidence interval.

MATERIALS AND METHODS

Study Subjects

A total of 76 CRC patients (38 with colon cancer and 38 with rectal cancer) who underwent surgery at the Department of
General Surgery of Peking Union Medical College Hospital from June 2012 to April 2014 were recruited. All included participants were pathologically confirmed with colon/rectal cancer. BMI was calculated as weight (kilograms) divided by height (square meters). Patients with acute inflammatory disease, chronic rheumatic diseases, or other malignant tumors and those with BMI <18 kg/m² were excluded from this study. In addition, 40 healthy subjects (18 kg/m² < BMI < 25 kg/m²) were collected from the physical examination center with normal liver, kidney, and heart function and normal routine blood and urine tests, and their systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also in the normal ranges. Informed consent was signed by all participants, and the study was approved by the ethics committee of Peking Union Medical College Hospital (No. S-364).

**Blood and Tissue Sample Collection and Processing**

Colorectal cancer patients were divided into NW + CRC (18 kg/m² < BMI < 25 kg/m², n = 42) and OW/OB + CRC (BMI ≥ 25 kg/m², n = 34) groups. All subjects had fasted overnight for at least 12 h, and blood samples were collected before the surgical operation. Serum was separated by centrifugation at 3,000 g for 10 min at 4°C and was stored in 1.5 mL Eppendorf tubes at −80°C for further analysis. In addition, sWAT and vWAT were obtained during the surgical procedure in nine OB + CRC patients and nine age-sex matched NW + CRC patients. Samples of adipose tissue were immediately frozen in liquid nitrogen and subsequently stored at −80°C for further study.

**Serum Biochemical Parameters and Adipokine Measurements**

Serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and fasting blood glucose (FBG) levels were determined by routine automated laboratory methods in our clinical laboratory. Serum adipokines including ZAG, HMW-ADPN, leptin, and TNF-α were measured by commercially available enzyme-linked immunosorbent assay kits (USCN Life Science Inc., Wuhan, China) according to the manufacturer’s instructions. The low limits of detection for ZAG, HMW-ADPN, leptin, and TNF-α were 1.80 ng/mL, 0.07 ng/mL, 0.06 ng/mL, and 6.50 pg/mL, respectively. The intra- and inter-assay coefficients of variation were 1.13 and 8.52% for ZAG, 0.59 and 4.60% for HMW-ADPN, 1.72 and 2.32% for leptin, and 2.07 and 2.76% for TNF-α.

**Total RNA Preparation and Reverse Transcription Quantitative PCR**

Total RNA was extracted from human sWAT and vWAT by using E.Z.N.A Total RNA Kit I (Omega, San Diego, CA, USA) according to the manufacturer’s recommendations. Total RNA concentrations were estimated by Nano Drop 2000C (Thermo, Forma, USA). Then, 1.0 µg of total RNA was reverse transcribed into cDNA by using 1.0 µl Omniscript reverse transcriptase (QIagen, Hilden, Germany), 10 U RNase inhibitor and an Oligo-dT primer (Promega, Madison, WI, USA) at 37°C for 60 min. PCR amplification was performed on an ABI 7500 PCR instrument (Applied Biosystems, CA, USA) with each gene in duplicate. The reaction conditions consisted of an initial denaturation step (10 min at 95°C) and a cycling step (denaturation for 15 s at 95°C and annealing and extending for 1 min at 60°C for 40 cycles). β-Actin was used for normalization, and all the primer sequences used were listed in Table S1 in Supplementary Material. The results are expressed as fold changes of Ct value relative to controls by using the 2−ΔΔCt formula (29).

**Statistical Analysis**

Data are shown as the mean ± SD or median with interquartile range. Normal distribution of the variables was evaluated using the Shapiro–Wilk test. Comparison of variables between two groups was performed by either the independent sample t-test or Mann–Whitney U test according to the data distribution. Univariate and multivariate logistic regression analyses were used to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of each variable for CRC. Cutoff point analysis, defined by the largest distance from the diagonal line of the ROC curve [sensitivity × (1 − specificity)], was used to identify the optimal value of serum ZAG levels that differentiated healthy people from patients with CRC. The sensitivity and specificity of the index for the cutoff point were also calculated. Stepwise multiple regression analysis was performed to explore the variables independently related to ZAG levels in serum and WAT. All statistical computations were run on SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.

**RESULTS**

**General Characteristics of Subjects in NW + CRC, OW/OB + CRC, and Control Groups**

The characteristics of the CRC patients and healthy controls have been summarized in Table 1. Generally, NW + CRC patients have a significantly higher age but lower HDL-C levels when compared with control subjects (all P < 0.05). As expected, patients in the OW/OB + CRC group presented with a higher body weight, BMI, SBP, and TG than those in the NW + CRC group (all P < 0.05). However, no significant difference was observed with regard to height, DBP, FBG, TC, or LDL-C in these two groups.

**Serum Levels of ZAG, Leptin, HMW-ADPN, and TNF-α in CRC Patients and Healthy Controls**

As shown in Figure 1A, serum ZAG levels in NW + CRC patients were 11.7% higher than in healthy controls (1.53 ± 0.30 vs. 1.37 ± 0.31 µg/mL, P < 0.05). In addition, serum levels of leptin in NW + CRC patients had a tendency to be lower compared with healthy controls (1.82 ± 1.85 vs. 2.13 ± 1.36 ng/mL, P = 0.07) (Figure 1B). No significant difference was found in serum HMW-ADPN and TNF-α levels between NW + CRC patients and healthy controls (Figures 1C,D).
TABLE 1 | General characteristics of subjects in NW + CRC, OW/OB + CRC, and control groups.

| Characteristics       | Controls (n = 40) | All CRC (n = 76) | NW + CRC (n = 42) | OW/ OB + CRC (n = 34) |
|-----------------------|------------------|-----------------|------------------|----------------------|
| Gender (M:F)          | 30/10            | 48/28           | 29/13            | 19/15                |
| Age (years)           | 63.6 ± 7.4       | 67.5 ± 10.8     | 67.9 ± 9.4a      | 67.1 ± 12.5          |
| Height (cm)           | 166.5 ± 8.0      | 166.3 ± 7.8     | 166.5 ± 6.3      | 165.9 ± 9.3          |
| Body weight (kg)      | 63.2 ± 7.8       | 69.3 ± 12.8     | 61.2 ± 6.3       | 79.3 ± 11.7b         |
| BMI (kg/m²)           | 22.5 ± 1.9       | 25.0 ± 3.9      | 22.0 ± 1.6       | 28.7 ± 2.5            |
| Hypertension (%)      | 0                | 33 (43.4%)      | 17 (40.5%)       | 16 (47.1%)           |
| Type 2 DM (%)         | 0                | 10 (13.2%)      | 4 (9.5%)         | 6 (17.6%)            |
| Cardiovascular disease (%) | 0          | 9 (11.8%)       | 4 (9.5%)         | 5 (14.7%)            |

SBP (mmHg) 121.3 ± 9.8 127.0 ± 14.6 123.4 ± 15.4 131.5 ± 12.4
DBP (mmHg) 74.7 ± 6.9 74.5 ± 9.8 73.5 ± 9.8 75.7 ± 9.7
FBG (mmol/L) 5.04 ± 0.43 5.65 ± 1.62 5.45 ± 1.50 5.89 ± 1.75
TC (mmol/L) 4.79 ± 0.59 4.81 ± 0.97 4.62 ± 0.75 5.04 ± 1.18
TG (mmol/L) 1.23 ± 0.50 1.37 ± 0.57 1.21 ± 0.52 1.59 ± 0.54
HDL-C (mmol/L) 1.37 ± 0.32 1.09 ± 0.23 1.13 ± 0.26 1.04 ± 0.18
LDL-C (mmol/L) 2.90 ± 0.48 2.96 ± 0.72 2.86 ± 0.67 3.07 ± 0.78

Values are mean ± SD.
NW, normal weight; OW/OB, overweight/obese; CRC, colorectal cancer; BMI, body mass index; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

As shown in Figures 1E–H, serum HMW-ADPN levels in OW/OB + CRC patients were significantly decreased by 23.5% (2.02 ± 1.19 vs. 2.64 ± 1.30 μg/mL, P < 0.05), while the leptin levels were significantly increased by 57.7% (2.87 ± 1.47 vs. 1.82 ± 1.90 ng/mL, P < 0.01) when compared with NW + CRC patients. However, no significant difference was observed in serum ZAG and TNF-α levels between these two groups.

Next, serum levels of the four adipokines were further analyzed in male and female subjects, separately. As shown in Figure S1 in Supplementary Material, for men, serum ZAG levels in NW + CRC patients were 22.2% higher (1.57 ± 0.31 vs. 1.28 ± 0.25 μg/mL, P < 0.05), while the leptin levels were 30.1% lower (1.20 ± 1.36 vs. 1.71 ± 1.10 ng/mL, P < 0.05) than in healthy controls. Serum HMW-ADPN levels in male OW/ OB + CRC patients were significantly decreased by 37.5% (1.67 ± 1.05 vs. 2.68 ± 1.41 μg/mL, P < 0.05), while the leptin levels were significantly increased by 86.1% (2.22 ± 1.29 vs. 1.20 ± 1.36 ng/mL, P < 0.01) when compared with NW + CRC patients. However, no significant difference was observed in serum ZAG, leptin, HMW-ADPN, and TNF-α levels in women across these three groups (Figure S2 in Supplementary Material).

Expression of ZAG, Leptin, HMW-ADPN, and TNF-α in sWAT and vWAT of NW + CRC and OB + CRC Patients

In our present study, the mRNA levels of ZAG, leptin, HMW-ADPN, and TNF-α were also measured in sWAT and vWAT from nine NW + CRC and nine OB + CRC patients. Baseline characteristics of the patients have been summarized in Table S2 in Supplementary Material. Our results showed that ZAG mRNA levels in sWAT were significantly lower in OB + CRC patients than in NW + CRC patients (reduced by 78.8%, P < 0.01) as presented in Figure 2A. Additionally, TNF-α mRNA levels in vWAT of OB + CRC patients were significantly increased by 2.8-fold when compared with NW + CRC patients (P < 0.05) (Figure 2H). No significant differences in HMW-ADPN or leptin mRNA levels in sWAT and vWAT were observed between these two groups (Figures 2B–G).

The Relationships Between Clinical Parameters and Serum ZAG Levels and ZAG mRNA Levels in sWAT and vWAT in CRC Patients

As shown in Table 2, a significant positive correlation between circulating ZAG levels and TNF-α levels was found after adjusting for age and sex in CRC patients (r = 0.27, P = 0.03). ZAG mRNA levels in sWAT were negatively associated with BMI (r = −0.55, P = 0.03), whereas ZAG mRNA levels in vWAT were positively correlated with BMI (r = 0.60, P = 0.01). In addition, ZAG mRNA levels in sWAT were also found to be positively associated with serum HMW-ADPN levels (r = 0.54, P = 0.03). No significant relationship between serum ZAG levels and BMI was found in CRC patients.

Next, stepwise multivariate linear regression was performed. As displayed in Table 3, CRC, TNF-α, and HDL-C were independent factors associated with serum ZAG levels after adjusting for age, gender, BMI, TC, TG, SBP, DBP, FBG, HDL-C, and LDL-C. Among them, the presence of CRC was found to be independently positively associated with serum ZAG levels (B = 0.24, P < 0.01), which was consistent with the higher serum ZAG levels in CRC patients as displayed in Figure 1A. Serum TNF-α levels were also independently positively associated with serum ZAG levels (B = 0.01, P < 0.01), which was also in accordance with the results shown in Table 2 by partial correlation analysis. In addition, BMI was independently negatively related to ZAG mRNA levels in sWAT but independently positively related to ZAG mRNA levels in vWAT, which was also consistent with the results demonstrated in Table 2.

Association of ZAG, Leptin, HMW-ADPN, and TNF-α with CRC Risks

Next, all subjects were stratified into trisections according to ZAG tertiles (lowest: <1.30 μg/mL; median: 1.30–1.51 μg/mL; highest: ≥1.51 μg/mL). As shown in Table 4, the CRC risk was 2.43-fold higher in subjects with the high ZAG level than those with the low serum ZAG levels (OR = 3.43, 95% CI 1.24–9.49, P = 0.02) after adjusting for age and gender (Model 1). This increased probability of CRC risk still remained after further adjusting for BMI, SBP, DBP, and FBG based on Model 1 (Model 2, OR = 3.96, 95% CI 1.28–12.27, P = 0.04) and TC, TG, HDL-C, and LDL-C based on Model 2 (Model 3, OR = 6.84, 95% CI 1.70–27.54, P = 0.03). In addition, serum leptin levels were also categorized into tertiles (lowest: <1.12 ng/mL; median: 1.12–2.92 ng/mL; highest: ≥2.92 ng/mL). As presented in Table 4, the probability of CRC
Fig. 1 | Serum levels of ZAG, leptin, HMW-ADPN, and TNF-α in NW + CRC patients and healthy controls (A–D) as well as in NW + CRC and OW/OB + CRC patients (E–H). Abbreviations: ZAG, zinc-α2-glycoprotein; HMW-ADPN, high-molecular-weight adiponectin; TNF-α, tumor necrosis factor-alpha; NW, normal weight; OW/OB, overweight/obese; CRC, colorectal cancer. All values are expressed as the median with the interquartile range.

Zhu et al. Adipokines in CRC Patients

Frontiers in Endocrinology | www.frontiersin.org April 2018 | Volume 9 | Article 190

risk decreased by 94.0% in participants with the highest leptin level compared with those with the lowest serum leptin levels (OR = 0.06, 95% CI 0.01–0.41, P = 0.01) after adjusting for age, gender, BMI, SBP, DBP, and FBG (Model 2). This decreased risk of CRC remained after further adjusting for TC, TG, HDL-C, and LDL-C based on Model 2 (Model 3, OR = 0.11, 95% CI 0.01–0.89, P = 0.04). However, no significant differences were found in the OR of CRC risks between the tertiles of HMW-ADPN and TNF-α levels.

**DISCUSSION**

Zinc-α2-glycoprotein is a 41-kDa secreted glycoprotein that was first identified in human plasma in 1961 (30). Previous studies have shown that ZAG is expressed at high levels in a variety of malignancies, such as prostate, breast, and lung cancer (20–22). Serum ZAG was found to be a potential biomarker for prostate cancer (23). Early in 2012, Agesen et al. found increased ZAG gene expression at the transcriptional levels in CRC tissues from Western populations, including Norwegian, American, and Australian populations (26). Further studies in Chinese populations also reported that ZAG was upregulated at the transcriptional and posttranscriptional levels in fresh colon cancer tissues (27), suggesting that ZAG might be a potential biomarker for CRC in both Western and Eastern populations. Consistent with its elevated expression in cancer tissues, Xue et al. also found higher serum ZAG levels in CRC patients than in healthy controls (28). Further analysis showed that there was a positive association between serum ZAG levels and CRC clinical stages (28). Another study performed by Ji et al. found that serum ZAG was elevated in CRC patients, and CRC patients with higher ZAG levels...
showed worse clinical outcomes (27). In our present study, we also found that serum ZAG levels were significantly increased in CRC patients with NW and CRC was found to be independently associated with serum ZAG levels. Based on these data, it is thus reasonable to assume that the elevated expression of ZAG in CRC tissues results in high serum ZAG levels, which may further promote CRC development. In addition, our study showed that the significantly higher serum ZAG levels only presented in male CRC patients, which is consistent with the epidemiological findings that men are at a higher risk of CRC.

Next, all subjects were stratified into trisections according to their serum ZAG tertiles. The results showed that the CRC risk was 2.43-fold higher in subjects with the highest ZAG level than those with the lowest serum ZAG levels after adjusting for age and gender (Model 1). This increased probability of CRC remained after further adjusting for BMI, SBP, DBP, and FBG based on Model 1 (Model 2, OR = 3.96) and TC, TG, HDL-C, and LDL-C based on Model 2 (Model 3, OR = 6.84), suggesting that ZAG overexpression is a significant risk factor for CRC, independent of other clinical pathological factors. Further analyses using ROC curves showed that the AUC of ZAG was 0.655. At the cutoff value of 1.42 µg/mL, the diagnostic value of ZAG had 62.2% sensitivity and 69.2% specificity. In accordance with our results, Ji et al. reported that serum ZAG was a useful biomarker for CRC within ROC curve areas of 0.9572 (95% CI 0.9173–0.9971) in a cohort of 534 Chinese individuals (27). Studies conducted by Xue et al. further found that the AUC of ZAG was 0.742 (95% CI 0.656–0.827), which was lower than the AUC of CEA (0.746, 95% CI 0.665–0.827) but higher than the AUC of CA19-9 (0.676, 95% CI 0.578–0.774) in a total of 160 Chinese subjects (28). All of these findings suggest that ZAG could be used as a potential serum biomarker for CRC.

Zinc-α2-glycoprotein is also a novel adipokine that can be secreted by adipose tissue. Decreased ZAG levels in sWAT of obese patients and its negative association with BMI have been previously reported (19, 31–33). In our present study, we observed for the first time that ZAG mRNA levels in sWAT of OB + CRC patients were also significantly decreased when compared with...
regression analysis found a negative relationship between NW lipoprotein cholesterol; BMI, body mass index; SBP, systolic blood pressure. The correlation between cancer; ZAG, zinc-α2-glycoprotein; HMW-ADPN, and tumor necrosis factor-alpha (TNF-α) in all subjects.

Table 3 | Multiple regression analysis for the variables independently related to serum ZAG and ZAG mRNA levels in sWAT and vWAT in CRC patients.

| Measurement | Lowest odds ratio (OR) [95% confidence interval (CI)] | Median OR [95% CI] | Highest OR [95% CI] | P for trend |
|-------------|------------------------------------------------------|--------------------|----------------------|------------|
| ZAG         | <0.14 to 0.84 | ≥0.30 to 0.84 | ≥1.00 to 1.04 | 0.02 |
| Leptin      | <0.12 | ≥0.12 to 0.92 | ≥0.90 to 0.99 | 0.02 |
| HMW-ADPN    | <0.18 | ≥0.18 to 0.89 | ≥0.75 to 0.99 | 0.02 |

Table 4 | Unconditional logistic regression analysis of colorectal cancer risks according to tertiles of zinc-α2-glycoprotein (ZAG), leptin, high-molecular-weight adiponectin (HMW-ADPN), and tumor necrosis factor-alpha (TNF-α) in all subjects.

Table 2 | Partial correlation analysis between ZAG levels in both serum and WAT and clinical parameters in CRC patients.

| Serum ZAG (n = 76) | sWAT ZAG (n = 18) | vWAT ZAG (n = 18) |
|---------------------|---------------------|---------------------|
| r       | P       | r       | P       | r       | P       |
| Age (years)         | -0.15 | 0.21 | -0.03 | 0.93 | -0.25 | 0.33 |
| BMI (kg/m²)         | -0.15 | 0.23 | -0.55 | 0.03 | 0.60 | 0.01 |
| SBP (mmHg)          | -0.04 | 0.75 | -0.32 | 0.25 | -0.29 | 0.29 |
| DBP (mmHg)          | -0.04 | 0.77 | -0.41 | 0.13 | 0.01 | 0.98 |
| FBG (mM/L)          | 0.04  | 0.77 | 0.04  | 0.88 | 0.03 | 0.91 |
| TC (mM/L)           | -0.04 | 0.77 | -0.21 | 0.46 | 0.26 | 0.35 |
| TG (mM/L)           | -0.02 | 0.10 | -0.08 | 0.80 | -0.30 | 0.29 |
| HDL-C (mM/L)        | 0.13  | 0.30 | -0.02 | 0.95 | -0.09 | 0.74 |
| LDL-C (mM/L)        | -0.16 | 0.17 | -0.14 | 0.63 | 0.28 | 0.31 |
| Serum ZAG (µg/mL)   | -    | -    | -0.10 | 0.73 | 0.08 | 0.77 |
| Serum leptin (ng/mL)| -0.02 | 0.84 | -0.52 | 0.06 | 0.52 | 0.06 |
| Serum HMW-ADPN (µg/mL) | 0.01 | 0.97 | 0.54 | 0.03 | -0.48 | 0.07 |
| Serum TNF-α (pg/mL) | 0.27 | 0.03 | -0.34 | 0.24 | -0.1 | 0.68 |

Values are age-sex-adjusted Spearman partial correlation coefficients. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ZAG, zinc-α2-glycoprotein; HMW-ADPN, high-molecular-weight-adiponectin; TNF-α, tumor necrosis factor-alpha; sWAT, subcutaneous white adipose tissue; vWAT, visceral white adipose tissue.

Bold font means p < 0.05.

Table 3 | Multiple regression analysis for the variables independently related to serum ZAG and ZAG mRNA levels in sWAT and vWAT in CRC patients.

| B            | SE of B | β   | P    |
|--------------|---------|-----|------|
| Serum ZAG (R² = 0.52) | |     |      |
| CRC (or 1)   | 0.24    | 0.06 | 0.34 | <0.01 |
| TNF-α        | 0.01    | 0.00 | 0.34 | <0.01 |
| HDL-C        | 0.31    | 0.10 | 0.31 | <0.01 |
| Constant     | 0.66    | 0.15 |      | <0.01 |
| ZAG mRNA in sWAT (R² = 0.298) | |     |      |
| BMI          | -10.00  | 4.10 | -0.55 | 0.03 |
| Constant     | 351.44  | 112.27 | 0.01 |
| ZAG mRNA in vWAT (R² = 0.553) | |     |      |
| BMI          | 243.68  | 66.76 | 0.70 | <0.01 |
| SBP          | -83.08  | 33.38 | -0.48 | 0.03 |
| Constant     | 4,763.52 | 4,120.78 | 0.27 |

Stepwise multiple regression analysis was used. Variables also entered into multiple regression analysis but not included in the equation: age, gender, BMI, total cholesterol, triglycerides, SBP, diastolic blood pressure, fasting blood glucose, low-density lipoprotein cholesterol, serum high-molecular-weight-adiponectin, and serum leptin.

NW + CRC patients. Further partial correlation and multiple regression analysis found a negative relationship between ZAG mRNA levels in sWAT and BMI, and BMI was independently negatively related to ZAG levels in sWAT. These results suggest that the decreased ZAG levels in sWAT and its relationship with BMI were observed both in simple OW/OB patients and in CRC patients. By contrast, ZAG mRNA levels in vWAT were found to be positively related with BMI in our present study. In contrast with our findings in CRC patients, previous studies in simple obese patients performed by Mracek and Selva et al. found that ZAG expression in vWAT was significantly lower in obese patients and showed a negative correlation with BMI (19, 34). Given these results together, we speculate that ZAG mRNA levels in sWAT and vWAT might play a different role in CRC patients. Previous studies by Balaz et al. have shown that ZAG in vWAT, but not in sWAT, is associated with whole-body insulin sensitivity (31). Although the biological mechanisms of the different role of sWAT and vWAT in CRC are still not well known, a possible explanation for this difference may be attributed to the much more severe insulin resistance of vWAT compared to sWAT (31). In addition, ZAG mRNA levels in vWAT were for the first time found to be negatively correlated with SBP in our present study. Further studies need to be done to validate this phenomenon.
After stratifying all subjects into trisections according to serum leptin tertiles, the probability of CRC risk was found to decrease by 94.0% in subjects with the highest leptin level compared to those with the lowest serum leptin levels after adjusting for age, gender, BMI, SBP, DBP, and FBG (Model 2, OR = 0.06). This decreased risk of CRC remained even after further adjusting for TC, TG, HDL-C, and LDL-C based on Model 2 (Model 3, OR = 0.11), suggesting that leptin might be a protective factor against CRC, which is independent of other clinical pathological factors. In line with our results, a case–control study performed by Joshi et al. in a South Korean population found a negative association between leptin and CRC risk (13). Additionally, studies in Western populations performed by Kumor and Salageanu et al. observed significantly lower serum leptin levels in CRC patients than controls (11, 12). Our present study also demonstrated that serum leptin levels have a lower trend in NW + CRC patients than healthy controls ($P = 0.07$).

Next, the CRC patients were further divided into OW/OB or NW groups. Interestingly, a significantly higher serum leptin levels was observed in OW/OB Chinese CRC patients when compared with NW CRC patients. Consistent with our results, studies performed by Stachowicz et al. in a total of 146 Caucasians with CRC also demonstrated that OW/OB CRC patients had statistically higher serum leptin levels than NW patients (35). It is well known that obese patients have markedly increased circulating leptin levels compared with NW controls (36). In our present study, we first found that the OW/OB CRC Chinese patients also had higher serum leptin than NW CRC patients.

ADPN is a 30-kDa protein hormone secreted exclusively from adipose tissue (37), and HMW-ADPN is now considered the most active form of adiponectin (38). ADPN has been shown to be decreased in obese subjects and is supposed to exert anti-inflammatory and anticancerous activity (39). Our present study also observed significantly decreased serum levels of HMW-ADPN

**FIGURE 3** | ROC curves of serum ZAG (A), leptin (B), HMW-ADPN (C), and TNF-α (D). ROC curves were derived by plotting the relationship between the specificity and the sensitivity at various cutoff levels. Abbreviations: ZAG, zinc-α2-glycoprotein; HMW-ADPN, high-molecular-weight-adiponectin; TNF-α, tumor necrosis factor-alpha; ROC, receiver operating characteristic; AUC, area under the curve.
in OW/OB + CRC patients compared to NW + CRC patients, similar to its profile in obese patients (40).

Tumor necrosis factor-alpha is a key pro-inflammatory cytokine produced by macrophages and secreted by adipocytes (41). It has been widely accepted that an obesity-associated low grade of chronic inflammation is an important contributing factor in CRC pathogenesis (42). However, in this study, no significant differences were found in the serum TNF-α level between NW + CRC patients and healthy controls, or between NW + CRC and OW/OB + CRC patients. In accordance with our results, Amor et al. measured the plasma levels of TNF-α in lean and obese subjects with and without CRC also found no significant change in plasma TNF-α levels between patients with CRC or obesity (43). Additionally, our study observed that TNF-α mRNA levels were upregulated in vWAT from OB + CRC patients compared to NW + CRC patients. Studies performed by Delgado et al. also reported that vWAT, but not sWAT, was an indicator of inflammation (44). These results suggest that TNF-α secreted by vWAT, instead of sWAT, may be involved in obesity-related CRC development.

In conclusion, our study found that serum ZAG levels were significantly increased in CRC patients. ZAG mRNA levels in sWAT were found to be significantly reduced in OB + CRC Chinese patients in comparison with NW + CRC patients. The patients with the highest tertile ZAG serum levels were more likely to have CRC. At the cutoff value of 1.42 μg/mL for serum ZAG, the sensitivity and specificity for differentiating patients with CRC from controls were 62.2 and 69.2%, respectively. Additional and more comprehensive studies are needed to explore the detailed mechanisms of the role of ZAG in CRC development.

ETHICS STATEMENT
Informed consent was signed by all participants and the study was approved by the ethics committee of Peking Union Medical College Hospital (No. S-364).

AUTHOR CONTRIBUTIONS
HZ designed the experiments and revised the primary manuscript. ML analyzed the data and wrote the primary manuscript. NZ performed the molecular biological experiments. HP, GL, NL, IW, HY, and KY collected the clinical materials and serum samples and finished the clinical and biochemical parameters measurements. FG designed the experiments, supervised the whole study, and revised the primary manuscript.

FUNDING
The study was supported by grants from the National Natural Science Foundation of China (Nos. 30600836, 81471024 for HZ, Nos. 30540036, 30771026, 81370898 for FG), the Beijing Natural Science Foundation (No. 7082079 and 7182130 for FG), the National Key Program of Clinical Science (WBYZ2011-873 for FG and HZ), and the PUMCH Foundation (2013-020 for FG).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fendo.2018.00190/full#supplementary-material.

REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2013) 65:86–108. doi:10.3322/caac.21262
2. Boyle P, Leon ME. Epidemiology of colorectal cancers. Br Med Bull (2002) 64:1–25. doi:10.1093/bmb/64.1.64
3. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev (2010) 11:19–30. doi:10.1111/j.1467-789X.2009.00613.x
4. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007) 16:2533–47. doi:10.1186/1055-9965-EP1-07-008
5. Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control (2010) 17:52–7. doi:10.1177/107327481001700107
6. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta (2011) 1807:664–78. doi:10.1016/j.bbabio.2010.11.004
7. van Kruipjdg JC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009) 18:2569–78. doi:10.1158/1055-9965.EPI-09-0372
8. Perez-Hernandez AI, Catalan V, Gomez-Ambrosi J, Rodriguez A, Fruehbeck G. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (2014) 5:65. doi:10.3389/fendo.2014.00065
9. Yamaji T, Iwasaki M, Sasazuki S, Tsuchane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res (2010) 70:5430–7. doi:10.1158/0008-5472.CAN-10-0178
10. Chen MW, Ye S, Zhao LL, Wang SY, Li YX, Yu CJ, et al. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol (2012) 29:3129–35. doi:10.1202/s12032-012-0280-2
11. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis (2009) 24:275–81. doi:10.1007/s00384-008-0605-y
12. Salageanu A, Tucureanu C, Lerescu L, Caras I, Pitica R, Gangura G, et al. Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life (2010) 3:416–20.
13. Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol (2014) 20:7941–9. doi:10.3748/wjg.v20.i24.7941
14. Cottam DR, Mattar SG, Barnas-Mitchell E, Eid G, Kuller L, Kelley DE, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg (2004) 14:589–600. doi:10.1381/096089204323093345
15. Kalbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fathar R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autoimmune tumor-promoting network in epithelial ovarian cancer cells. Cancer Res (2007) 67:585–92. doi:10.1158/0008-5472.CAN-06-2941
16. Davies FE, Rollinson SJ, Rawstorn AC, Roman E, Richards S, Drayson M, et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol (2000) 18:2843–51. doi:10.1200/JCO.2000.18.15.2843
17. Kim S, Keku TO, Martin C, Galanko J, Wooley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 68:323–8. doi:10.1158/0008-5472.CAN-07-2924
18. Mracek T, Gao D, Tzavvari T, Rao Y, Xiao X, Stocker C, et al. Downregulation of zinc-[alpha]2-glycoprotein in adipose tissue and liver of obese ob/ob mice
and by tumour necrosis factor-alpha in adipocytes. *J Endocrinol* (2010) 204:165–72. doi:10.1677/JOE-09-0299

19. Selva DM, Leducue A, Hernandez C, Baena JA, Fort JM, Simo R. Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. *J Clin Endocrinol Metab* (2009) 94:4499–507. doi:10.1210/jc.2009-0758

20. Falabella FS, Spina M, Pignatiello C, Noci S, Conti B, Pastorino U, et al. AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status. *Oncogene* (2008) 27:1650–6. doi:10.1038/sj.onc.1210775

11. Henshall SM, Horvath LG, Quinn DJ, Eggleton SA, Grygiel JJ, Stricker PD, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. *J Natl Cancer Inst* (2006) 98:1420–4. doi:10.1093/jnci/djI378

22. Dubois V, Delort L, Mischellany F, Jard B, Billard H, Lequeux C, et al. Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? *Anticancer Res* (2010) 30:2919–25.

23. Bondar OP, Barnsidge DR, Klee EW, Davis BJ, Klee GG. LC-MS/MS quantification of Zn-alpha2-glycoprotein: a potential serum biomarker for prostate cancer. *Clin Chem* (2007) 53:673–8. doi:10.1373/clinchem.2006.079681

24. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. *Clin Cancer Res* (2001) 7:486–53.

25. Dizzi-Izra I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-Otin C. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. *Eur J Cancer* (1993) 29A:1256–60. doi:10.1016/0959-8489(93)90068-Q

26. Aagesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skothem RI, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. *Gut* (2012) 61:1560–7. doi:10.1136/gutjnl-2011-301179

27. Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. *Carcinogenesis* (2013) 34:1265–72. doi:10.1093/carcin/bgt056

28. Xue Y, Yu F, Yan D, Cui F, Tang H, Wang X, et al. Zinc-alpha-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population. *Int J Mol Sci* (2014) 16:691–703. doi:10.3390/ijms16010691

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. *Methods* (2001) 25:402–8. doi:10.1006/meth.2001.1262

30. Burgi W, Schmid K. Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. *J Biol Chem* (1961) 236:1066–74.

31. Balaz M, Vician M, Janakova Z, Kurdirova T, Surova M, Intrich R, et al. Subcutaneous adipose tissue zinc-alpha2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. *Obesity (Silver Spring)* (2014) 22:1821–9. doi:10.1002/oby.20764

32. Ceperuelo-Mallafre V, Naf S, Escote X, Caubet E, Gomez JM, Miranda M, et al. Circulating and adipose tissue gene expression of zinc-alpha2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. *J Clin Endocrinol Metab* (2009) 94:5062–9. doi:10.1210/jc.2009-0764

33. Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS, et al. Zinc-[alpha]2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. *Int J Obes (Lond)* (2009) 33:1023–30. doi:10.1038/ijo.2009.141

34. Mracek T, Ding Q, Tzanavari T, Kos K, Pinkney J, Wilding J, et al. The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. *Clin Endocrinol (Oxf)* (2010) 72:334–41. doi:10.1111/j.1365-2265.2009.03658.x

35. Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Niedworok E, Fatyga E, Muc-Wierzgon M. Leptin and its receptors in obese patients with colorectal cancer. *J Biol Regul Homeost Agents* (2010) 24:287–95.

36. Pan WW, Myers MJ. Leptin and the maintenance of elevated body weight. *Nat Rev Neurosci* (2018) 19:95–105. doi:10.1038/nrn.2017.160

37. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). *Biochem Biophys Res Commun* (1996) 221:286–9. doi:10.1006/bbrc.1996.0587

38. Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner U, Scholmerich J, et al. Different effects of adiponectin isoforms in human mononocytic cells. *J Leukoc Biol* (2006) 79:803–8. doi:10.1189/jlb.0905521

39. Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M, et al. Changed adipocytokine concentrations in colorectal tumor patients and morbidity obese patients compared to healthy controls. *BMC Cancer* (2012) 12:545. doi:10.1186/1471-2407-12-545

40. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? *Diabetes Care* (2003) 26:2442–50. doi:10.2337/diabcare.26.8.2442

41. Guffrey CR, Fan D, Singh UP, Murphy EA. Linking obesity to colorectal cancer: recent insights into plausible biological mechanisms. *Curr Opin Clin Nutr Metab Care* (2013) 16:595–600. doi:10.1097/MCO.0b013e328362d10b

42. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature* (2004) 431:405–6. doi:10.1038/431405a

43. Amor S, Iglesias-de LCM, Ferrero E, Garcia-Villar O, Barrios V, Fernandez N, et al. Peritumoral adipose tissue as a source of inflammatory and angiogenic factors in colorectal cancer. *Int J Colorectal Dis* (2016) 31:365–75. doi:10.1007/s00384-015-2420-6

44. Delgado C, Chertow GM, Kaysen GA, Dalrymple LS, Kornak J, Grimes B, et al. Associations of body mass index and body fat with markers of inflammation and nutrition among patients receiving hemodialysis. *Am J Kidney Dis* (2017) 70:817–25. doi:10.1053/j.ajkd.2017.06.028

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhu, Liu, Zhang, Pan, Liu, Li, Wang, Yang, Yan and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.